Notably, patients with bone-marrow-failure syndrome have also been observed to be at a high risk of developing acute myeloid leukemia.62 Thus, ERCC6L2 seems to be a strong candidate as a putative tumor suppressor. Here, ERCC6L2 is linked to bone marrow failure syndrome.